-
公开(公告)号:PL186721B1
公开(公告)日:2004-02-27
申请号:PL32717596
申请日:1996-12-11
Applicant: BASF AG
Inventor: AMBERG WILHELM , BARLOZZARI TERESA , BERNARD HARALD , BUSCHMANN ERNST , HAUPT ANDREAS , HEGE HANS-GUENTHER , JANSSEN BERND , KLING ANDREAS , LIETZ HELMUT , RITTER KURT , ULLRICH MARTINA , WEYMANN JUERGEN , ZIERKE THOMAS
Abstract: Novel peptides of the formula R R N-CHX-CO-A-B-D-E-(G)s-K in which R , R , A, B, D, E, G, K, X, and s have the meanings stated in the description, and the preparation thereof are described. The novel peptides have an antineoplastic effect.
-
公开(公告)号:DE10137017A1
公开(公告)日:2003-02-20
申请号:DE10137017
申请日:2001-07-30
Applicant: BASF AG
Inventor: RAULS MATTHIAS , GELDER RICHARD VAN , WAGNER KATRIN , BERNARD HARALD
IPC: B01D9/02 , B01D9/00 , C07C403/00 , C07C403/08 , C07C403/14 , C07C403/20 , B01J19/10
Abstract: Production of crystals with an average particle size below 100 micro m comprises crystallizing a compound from a solution or suspension while exposing it to ultrasound directly applied through a sonotrode and while maintaining a specific stirring power.
-
公开(公告)号:HU0104010A2
公开(公告)日:2002-03-28
申请号:HU0104010
申请日:1999-10-16
Applicant: BASF AG
Inventor: BERNARD HARALD , DR RIECHERS HARTMUT
Abstract: A process for racemate resolution of 2-hydroxypropionic acids by reacting the racemic acid with an optically active base and subsequently separating off a diastereomeric salt of acid and base comprises using 1-(4-chlorophenyl)ethylamine as optically active base.
-
公开(公告)号:SK5292001A3
公开(公告)日:2001-10-08
申请号:SK5292001
申请日:1999-10-16
Applicant: BASF AG
Inventor: BERNARD HARALD , RIECHERS HARTMUT
Abstract: A process for racemate resolution of 2-hydroxypropionic acids by reacting the racemic acid with an optically active base and subsequently separating off a diastereomeric salt of acid and base comprises using 1-(4-chlorophenyl)ethylamine as optically active base.
-
公开(公告)号:GR3032630T3
公开(公告)日:2000-05-31
申请号:GR20000400328
申请日:2000-02-10
Applicant: BASF AG
Inventor: AMBERG WILHELM , BERNARD HARALD , BUSCHMANN ERNST , HAUPT ANDREAS , JANITSCHKE LOTHAR , JANSSEN BERND , KARL ULRICH , KLING ANDREAS , MUELLER STEFAN , DE POTZOLLI BERND , RITTER KURT , THYES MARCO , ZIERKE THOMAS
Abstract: PCT No. PCT/EP95/01577 Sec. 371 Date Nov. 4, 1996 Sec. 102(e) Date Nov. 4, 1996 PCT Filed Apr. 26, 1995 PCT Pub. No. WO95/30691 PCT Pub. Date Nov. 16, 1995The compound Me2Val-Val-MeVal-Pro-Pro-NHBzlxHCl is described. It is prepared from Z-Val-Val-MeVal-Pro-OR1 where Z and R1 have the meanings stated in the description. The compound shows antineoplastic activity.
-
公开(公告)号:PT758342E
公开(公告)日:2000-04-28
申请号:PT95917963
申请日:1995-04-26
Applicant: BASF AG
Inventor: JANSSEN BERND , ZIERKE THOMAS , ERNST BUSCHMANN DR , AMBERG WILHELM , BERNARD HARALD , HAUPT ANDREAS , JANITSCHKE LOTHAR , KARL ULRICH , KLING ANDREAS , MULLER STEFAN , POTZOLLI BERND DE , RITTER KURT , THYES MARCO
Abstract: PCT No. PCT/EP95/01577 Sec. 371 Date Nov. 4, 1996 Sec. 102(e) Date Nov. 4, 1996 PCT Filed Apr. 26, 1995 PCT Pub. No. WO95/30691 PCT Pub. Date Nov. 16, 1995The compound Me2Val-Val-MeVal-Pro-Pro-NHBzlxHCl is described. It is prepared from Z-Val-Val-MeVal-Pro-OR1 where Z and R1 have the meanings stated in the description. The compound shows antineoplastic activity.
-
公开(公告)号:ES2141351T3
公开(公告)日:2000-03-16
申请号:ES95917963
申请日:1995-04-26
Applicant: BASF AG
Inventor: AMBERG WILHELM , BERNARD HARALD , BUSCHMANN ERNST , HAUPT ANDREAS , JANITSCHKE LOTHAR , JANSSEN BERND
Abstract: PCT No. PCT/EP95/01577 Sec. 371 Date Nov. 4, 1996 Sec. 102(e) Date Nov. 4, 1996 PCT Filed Apr. 26, 1995 PCT Pub. No. WO95/30691 PCT Pub. Date Nov. 16, 1995The compound Me2Val-Val-MeVal-Pro-Pro-NHBzlxHCl is described. It is prepared from Z-Val-Val-MeVal-Pro-OR1 where Z and R1 have the meanings stated in the description. The compound shows antineoplastic activity.
-
公开(公告)号:DE59507578D1
公开(公告)日:2000-02-10
申请号:DE59507578
申请日:1995-04-26
Applicant: BASF AG
Inventor: AMBERG WILHELM , BERNARD HARALD , BUSCHMANN ERNST , HAUPT ANDREAS , JANITSCHKE LOTHAR , JANSSEN BERND , KARL ULRICH , KLING ANDREAS , MUELLER STEFAN , DE POTZOLLI BERND , RITTER KURT , THYES MARCO , ZIERKE THOMAS
Abstract: PCT No. PCT/EP95/01577 Sec. 371 Date Nov. 4, 1996 Sec. 102(e) Date Nov. 4, 1996 PCT Filed Apr. 26, 1995 PCT Pub. No. WO95/30691 PCT Pub. Date Nov. 16, 1995The compound Me2Val-Val-MeVal-Pro-Pro-NHBzlxHCl is described. It is prepared from Z-Val-Val-MeVal-Pro-OR1 where Z and R1 have the meanings stated in the description. The compound shows antineoplastic activity.
-
公开(公告)号:DE59603295D1
公开(公告)日:1999-11-11
申请号:DE59603295
申请日:1996-07-12
Applicant: BASF AG
Inventor: AMBERG WILHELM , BERNARD HARALD , BUSCHMANN ERNST , HAUPT ANDREAS , JANSSEN BERND , ULRICH KARL , KLING ANDREAS , MUELLER STEFAN , RITTER KURT , ZIERKE THOMAS
IPC: C07K1/02 , C07K1/12 , C07K5/06 , C07K5/078 , C07K5/08 , C07K5/083 , C07K5/10 , C07K5/103 , C07K7/06
Abstract: PCT No. PCT/EP96/03073 Sec. 371 Date Jan. 13, 1998 Sec. 102(e) Date Jan. 13, 1998 PCT Filed Jul. 12, 1996 PCT Pub. No. WO97/05162 PCT Pub. Date Feb. 13, 1997A process for preparing pentapeptides of the formula I where A and R1-R3 have the stated meanings, comprises assembling the pentapeptide stepwise starting from a prolinamide of the formula II where R1 and R2 have the abovementioned meanings, and eliminating the group -NR1R2 by hydrolysis where appropriate the peptide obtained in this way.
-
公开(公告)号:HU9802570A2
公开(公告)日:1999-04-28
申请号:HU9802570
申请日:1996-07-12
Applicant: BASF AG
Inventor: AMBERG WILHELM , BERNARD HARALD , BUSCHMANN ERNST , HAUPT ANDREAS , JANSSEN BERND , KLING ANDREAS , MUELLER STEFAN , RITTER KURT , ULRICH KARL , ZIERKE THOMAS
IPC: C07K1/02 , C07K1/12 , C07K5/06 , C07K5/078 , C07K5/08 , C07K5/083 , C07K5/10 , C07K5/103 , C07K7/06
Abstract: PCT No. PCT/EP96/03073 Sec. 371 Date Jan. 13, 1998 Sec. 102(e) Date Jan. 13, 1998 PCT Filed Jul. 12, 1996 PCT Pub. No. WO97/05162 PCT Pub. Date Feb. 13, 1997A process for preparing pentapeptides of the formula I where A and R1-R3 have the stated meanings, comprises assembling the pentapeptide stepwise starting from a prolinamide of the formula II where R1 and R2 have the abovementioned meanings, and eliminating the group -NR1R2 by hydrolysis where appropriate the peptide obtained in this way.
-
-
-
-
-
-
-
-
-